NTRA — Natera, Inc.

Summary of Natera's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Natera reported $592 million in revenue for Q3 2025, a 35% increase year-over-year.
• Gross Margin: Gross margin improved to 64.9%, up 1.5 percentage points from Q2 and nearly 3 percentage points from Q3 2024.
• Clinical MRD Tests: The company processed 202,000 clinical MRD tests, representing a growth of 21,500 units from Q2.
• Free Cash Flow: The company raised its free cash flow guidance to approximately $100 million for the full year.
• Accounts Receivable: Days Sales Outstanding (DSO) improved to a record 49 days, down from 57 days in Q2.

2. Strategic Updates and Business Highlights

• Product Growth: Continued strong growth in the Signatera product line, with record unit growth and ASPs reaching approximately $1,200.
• Fetal Focus Expansion: Launched an expanded Fetal Focus test covering over 20 genes, following positive feedback on the initial 5-gene panel.
• Clinical Trials: Plans to submit 7 new MolDx submissions by year-end, potentially worth $250 million to $300 million in gross profit.
• Oncology Advancements: Significant data from the IMvigor011 trial presented at ESMO, supporting Signatera's role in guiding treatment decisions post-surgery for bladder cancer.

3. Forward Guidance and Outlook

• Revenue Guidance: Natera raised its 2025 revenue guidance by $160 million, now expecting between $2.18 billion and $2.26 billion.
• Gross Margin Guidance: Adjusted gross margin guidance to 62%-64%.
• Operational Expenses: Modestly increased OpEx guidance due to one-time expenses totaling around $60 million, with a focus on R&D investments.
• Volume Growth: Anticipates maintaining strong volume growth in women's health and organ health, with Signatera expected to continue its upward trend.

4. Bad News, Challenges, or Points of Concern

• One-Time Expenses: The increase in operational expenses includes one-time costs that may not recur, which could impact future profitability.
• Market Competition: The presence of competitors in the prenatal and oncology testing markets poses ongoing challenges, particularly with new entrants gaining traction.
• Regulatory Risks: The path to NCCN guidelines and broader payer adoption remains uncertain, despite strong clinical data.

5. Notable Q&A Insights

• Fetal Focus Test: The decision to expand the Fetal Focus test was based on positive customer feedback and readiness from R&D.
• Signatera Adoption: Strong growth in new patient starts continues, with significant interest across multiple tumor types, particularly following recent clinical data releases.
• Biomarker Bills Impact: The potential impact of biomarker reimbursement bills is expected to grow in 2026, with ongoing traction in commercial payer coverage.
• VEGA Trial Expectations: The VEGA trial is expected to read out in 2027, with confidence in the study design and assay performance based on prior data.

Overall, Natera's Q3 2025 results reflect strong growth and strategic advancements, although challenges remain in competition and regulatory landscapes. The company is optimistic about future performance, supported by robust clinical data and ongoing product innovations.